Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma

Steven M. Horwitz, MD
Published: Tuesday, Oct 04, 2016



Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

However, it is only effective for some people, says Horwitz.

Recently, studies have begun investigating novel agents in combination with CHOP. Questions still remain regarding if CHOP is a reasonable backbone and if it improves outcomes for all patients or just specific subgroups of patients, says Horwitz


Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

However, it is only effective for some people, says Horwitz.

Recently, studies have begun investigating novel agents in combination with CHOP. Questions still remain regarding if CHOP is a reasonable backbone and if it improves outcomes for all patients or just specific subgroups of patients, says Horwitz

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x